About our research:
Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordic region.
In January 2026, our center was awarded Clinical Trial Center of the Year (Årets Senter) in Norway. The center contributes to approximately 5% of all global industry-sponsored myeloma trials.
Since 2015, Oslo Myeloma Center has enrolled over 1019 patients in 67 clinical studies, including newly diagnosed and relapsed/refractory patients across Phase 1, 2, 3 and 4 trials.
| Year | Patient Number |
| 2015 | 37 |
| 2016 | 67 |
| 2017 | 83 |
| 2018 | 98 |
| 2019 | 120 |
| 2020 | 83 |
| 2021 | 82 |
| 2022 | 105 |
| 2023 | 147 |
| 2024 | 110 |
| 2025 | 78 |
| February 2026 | 9 |
Number of patients included in the different phases by February 2026:
Phase 1 - 135 patients
Phase 2 - 330 patients
Phase 3 - 481 patients
Phase 4: 73 Patients
We maintain a comprehensive myeloma registry that includes both prospective and retrospective data. Additionally, our biobank collects materials that support translational research nationally.